CRISPR Therapeutics CRSP Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's other income, net (note 6)?
- CRISPR Therapeutics (CRSP) reported other income, net (note 6) of $8.16M in Q1 2026.
- How has CRISPR Therapeutics's other income, net (note 6) changed year-over-year?
- CRISPR Therapeutics's other income, net (note 6) decreased by 39.8% year-over-year, from $13.54M to $8.16M.
- What is the long-term trend for CRISPR Therapeutics's other income, net (note 6)?
- Over 4 years (2021 to 2025), CRISPR Therapeutics's other income, net (note 6) has grown at a 94.9% compound annual growth rate (CAGR), from $6M to $86.61M.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.